It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.

Problems at Lupin’s plant in Goa, India, hit the drugmaker’s latest earnings with a double whammy, undercutting its U.S. sales while raising costs.

India’s Granules bought a U.S. R&D facility in 2014 and is now ready to add manufacturing as part of plans to expand significantly in the U.S. market.…

India’s Dr. Reddy’s Laboratories, which has been whiplashed repeatedly by FDA actions against its plants, saw its sales in the U.S. fall markedly in the last…

Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth…

India’s Granules will do a significant expansion of its API bulk drug site in Vishakhapatnam, and is getting substantial help from the International Finance…

China’s Kangmei Pharma, a company focused on oral traditional Chinese medicine, intends to pour $146 million into a healthcare industry fund.

Perrigo, which is under pressure from investors to shore up its finances, will raise a little cash with a deal to sell an API plant to India’s Strides Shasun.

Takeda says its new oral multiple myeloma drug Ninlaro is on course to become its biggest-ever cancer product.